Prostate cancer is a public health problem in Senegal. It is one of the most common cancers in men and can be detected early by PSA measurement and confirmed by the pathological study which specifies the histological type and evaluates the histoprognostic scores (Gleason and pTNM). We did not find any anatomopathological study highlighting a link between the PSA t rate and histoprognostic Gleason scores in Senegal. Objective: We carried out this work aimed at determining whether there is a correlation between the PSA t rate and the histoprognostic Gleason score, in our context. Methodology: This is a retrospective, descriptive and analytical study conducted from January 2013 to October 2021, based on histologically proven prostate cancer cases with a specified PSA level, diagnosed in the pathological anatomy and cytology laboratory of Aristide Le Dantec hospital. Results: We identified 654 cases of prostate cancer. The average age was 68.59 ± 5.8 years with extremes of 40 years to 92 years. More than half of our cohort presented a clinical stage T2c, i.e. 56.94%. The average prostate volume on ultrasound was 81.81 ± 66 cc. The median PSA t was 110.5 ng/ml, with extremes ranging from 2 ng/ml to 74,770 ng/ml. Prostatic adenocarcinoma was the only histological type found in our patients. There was a predominance of Gleason score 6 (PICU grade group 1) observed in 35.17% of patients. Well-differentiated cancers were predominant and represented 35.17%. There was a statistically significant positive correlation between PSA t level and Gleason score (Spearman’s Rho = 0.305, p = 0.000). Conclusion: This study shows that in the Senegalese population, in patients with prostate cancer, the higher the PSA t level rises above normal, the higher the Gleason score tends to be.
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
IARC/OMS (2021) Global Cancer Observatory. Cancer Today. https://gco.iarc.fr/today/online-analysismap?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=1&cancer=27&type=0&statistic=5&prevalence=0&population_group=0&ages_group[]=0&ages_group[]=17&nb_items=10&gr
[3]
Bouri, N.V., Ba, O., Dieme, J.L., Mbengue, M., Boye, A., Fall, T., et al. (2017)Inventory of Fixtures of the Tumor Registry in Senegal: Assessment after 6 Years of Online Registration. Journal of Respiratory Diseases, 34, A75. https://doi.org/10.1016/j.rmr.2016.10.156
[4]
Fournier, G., Valeri, A., Mangin, P. and Cussenot, O. (2004) Prostate Cancer. Epidemiology. Risk Factors. Anatomopathology. Annals of Urology, 38, 187-206. https://doi.org/10.1016/j.anuro.2004.07.001
[5]
Kumar, V., Abbas, A.K. and Aster, J.C. (2014) Robbins and Cotran Pathologic Basis of Disease, Professional Edition E-Book. 9th Edition, Elsevier, New York.
[6]
Camilo, A. and Thomas, P. (2016) Mémento de pathologie. 4e Édition, Éditions Vernazobres-Grego, Paris.
[7]
Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., et al. (2013)Cancer de la prostate : Quelle prise en charge au Sénégal ? Progrès en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
[8]
Mohammed, U., Rasheed, M.W., Adegboye, A.T., Abdullahi, K., Sahabi, S.M., To, M., et al. (2024)Correlation of Serum PSA with Gleason Score and Gleason Group Grade in Patients with Prostate Adenocarcinoma at Sokoto North-Western Nigeria. International Journal of Recent Innovations in Medicine and Clinical Research, 2, 6-13. https://doi.org/10.18231/j.ijrimcr.2024.002
[9]
Ndiaye, M., Sow, O., Thiam, A., Sarr, A., Gaye, O., Sine, B., et al. (2020)Cancer de la prostate au Centre Hospitalier Universitaire Aristidie Le Dantec de Dakar : Aspects épidemiologiques sur les cinq dernières années. AnnalesAfricaines de Médecine, 14, e4004-e4009.
[10]
Amégbor, K., Yao Seddoh, T., Tengué, K., Songne-Gnamkoulamba, B., Napo-Koura, G. AND James, K. (2009) Épidémiologie et histopronostic du cancer de la prostate au Togo : À propos de 202 cas diagnostiqués au laboratoire d’anatomie pathologique du CHU Tokoin de Lomé. Progrès en Urologie, 19, 112-115. https://doi.org/10.1016/j.purol.2008.10.008
[11]
Alexander, R.B., Maguire, M.G., Epstein, J.I. and Walsh, P.C. (1989) Pathological Stage Is Higher in Older Men with Clinical Stage B1 Adenocarcinoma of the Prostate. Journal of Urology, 141, 880-882. https://doi.org/10.1016/S0022-5347(17)41038-X
[12]
Aprikian, A.G., Zhang, Z.F. and Fair, W.R. (1994) Prostate Adenocarcinoma in Men Younger than 50 Years. A Retrospective Review of 151 Patients. Cancer, 74, 1768-1777. https://doi.org/10.1002/1097-0142(19940915)74:6<1768::AID-CNCR2820740620>3.0.CO;2-9
[13]
Parker, P.M., Rice, K.R., Sterbis, J.R., Chen, Y., Cullen, J., McLeod, D.G., et al. (2011)Prostate Cancer in Men Less than the Age of 50: A Comparison of Race and Outcomes. Urology, 78, 110-115. https://doi.org/10.1016/j.urology.2010.12.046
[14]
Catalona, W.J., Richie, J.P., Ahmann, F.R., Hudson, M.A., Scardino, P.T., Flanigan, R.C., et al. (1994)Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. Journal of Urology, 151, 1283-1290. https://doi.org/10.1016/S0022-5347(17)35233-3
[15]
Jalloh, M., Thiaw, G., Bathily, E.H.A.L., Dial, C., Ndoye, M., Diallo, A., et al. (2018)Corrélation entre score de Gleason biopsique et métastases osseuses à la scintigraphie dans le cancer de la prostate.Revue Africained’Urologieetd’Andrologie, 1, 501-508.
[16]
Kabore, F.A., Zango, B., Sanou, A., Yameogo, C. and Kirakoya, B. (2011) Prostate Cancer Outcome in Burkina Faso. Infectious Agents and Cancer, 6, Article No. S6. https://doi.org/10.1186/1750-9378-6-S2-S6
[17]
Loko, F., Hodonou, R., Akpaka, R., Hounnasso, P., Adisso, S. and Akpo, C. (2011) Valeur predictive du PSA dans le diagnostic du cancer de la prostate chez les sujets Beninois. International Journal of Biological and Chemical Sciences, 5, 512-523. https://doi.org/10.4314/ijbcs.v5i2.72096
[18]
Gueye, S.M., Jalloh, M., Labou, I., Niang, L., Kane, R. and Ndoye, M. (2004) Profil clinique du cancer de la prostate au Sénégal. African Journal of Urology, 10, 203-207.
[19]
Gurumurthy, D., Maggad, R. and Patel, S. (2015) Prostate Carcinoma: Correlation of Histopathology with Serum Prostate Specific Antigen. Science Journal of Clinical Medicine, 4, 1-5. https://doi.org/10.11648/j.sjcm.s.2015040401.11
[20]
Epstein, J.I. and Netto, G.J. (2014) Biopsy Interpretation of the Prostate. Lippincott Williams & Wilkins, Philadelphia.
[21]
Gretzer, M.B. and Partin, A.W. (2003) PSA Markers in Prostate Cancer Detection. Urologic Clinics of North America, 30, 677-686. https://doi.org/10.1016/S0094-0143(03)00057-0
[22]
Ndiaye, M. (2018) Cancers prostatiques métastatiques sous hormonothérapie : Facteurs influençant la résistance à la castration. Master’s Thesis, Cheikh Anta Diop, Dakar.
[23]
Ndong, B., Mbodj, M., Mbaye, G., Ndoye, O., Bathily, E.H.A.L., Diouf, L.A.D., et al. (2012)Place de la scintigraphie osseuse dans le bilan d’extension des métastases des cancers de la prostate au Sénégal: Étude préliminaire à propos de 45 cas. Médecine Nucléaire, 36, 586-590. https://doi.org/10.1016/j.mednuc.2012.05.012
[24]
McNeal, J.E. (1969) Origin and Development of Carcinoma in the Prostate. Cancer, 23, 24-34. https://doi.org/10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1
[25]
Okolo, C.A., Akinosun, O.M., Shittu, O.B., Olapade-Olaopa, E.O., Okeke, L.I., Akang, E.E.U., et al. (2008)Correlation of Serum PSA and Gleason Score in Nigerian Men with Prostate Cancer. African Journal of Urology, 14, 15-22. https://doi.org/10.1007/BF02994508
[26]
Čamdžić, N., Kuskunović-Vlahovljak, S., Dorić, M., Radović, S., Lazović Salčin, E. and Babić, M. (2021) Serum Total Prostate-Specific Antigen (tPSA): Correlation with Diagnosis and Grading of Prostate Cancer in Core Needle Biopsy. MedicinskiGlasnik, 18, 122-127.
[27]
Yarney, J., Vanderpuye, V. and Mensah, J. (2013) Clinicopathologic Features and Determinants of Gleason Score of Prostate Cancer in Ghanaian Men. Urologic Oncology: Seminars and Original Investigations, 31, 325-330. https://doi.org/10.1016/j.urolonc.2011.01.018
[28]
Lovely, J., Suma, M.T., Santa, S. and Soudan, V.M. (2017) Gleason’s Grading of Carcinoma Prostate with PSA Correlation. JMSCR, 5, 27634-27639. https://doi.org/10.18535/jmscr/v5i9.44
[29]
Blackwell, K.L., Bostwick, D.G., Myers, R.P., Zincke, H. and Oesterling, J.E. (1994) Combining Prostate Specific Antigen with Cancer and Gland Volume to Predict more Reliably Pathological Stage: The Influence of Prostate Specific Antigen Cancer Density. Journal of Urology, 151, 1565-1570. https://doi.org/10.1016/S0022-5347(17)35303-X
[30]
Partin, A.W., Carter, H.B., Chan, D.W., Epstein, J.I., Oesterling, J.E., Rock, R.C., et al. (1990)Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia. Journal of Urology, 143, 747-752. https://doi.org/10.1016/S0022-5347(17)40079-6
